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Background. Evidence is accumulating in favour of a link between erectile dysfunction (ED) and coronary artery diseases. We
investigated the presence of cardiac injury in patients who have had arteriogenic and nonarteriogenic ED using the hs-Tn levels.
Methods.The diagnosis of ED was based on the International Index of Erectile Function 5-questionnaire (IIF-5) and patients were
classified as arteriogenic (A-ED, 𝑛 = 40), nonarteriogenic (NA-ED, 𝑛 = 48), and borderline (BL-ED, 𝑛 = 32) patients in relation
to the results of echo-color-Doppler examination of cavernous arteries. The level of hs-TnT and hs-TnI was measured in 120 men
with a history of ED of less than one year with no clinical evidence of cardiac ischemic disease. Results.The levels of both hs-TnT
and hs-TnI were within the reference range and there was no significant (𝑃 > 0.05) difference between patients of the three groups.
The hs-CRP values were higher in A-ED men compared with NA-ED (𝑃 = 0.048) but not compared with BL-ED (𝑃 = 0.136)
and negatively correlated with IIF-5 (𝑟 = −0.480; 𝑃 = 0.031). Conclusions. In ED patients of the three groups the measurement of
hs-Tn allows us to exclude the presence of cardiac involvement at least when the history of ED is less than one year and the men
are without atherosclerotic risk factors.
1. Introduction
Erectile dysfunction (ED) is now considered an early man-
ifestation of a largely subclinical systemic vascular disorder
affecting also the penile arteries. Indeed, ED shares with other
vascular diseases, mainly coronary artery disease (CAD),
common risk factors [1–4] and a similar pathogenic involve-
ment of the NO pathway that leads to early impairment of
endothelium-dependent vasodilatation and late obstructive
vascular changes [5–8].
Cardiac troponin T (TnT) and troponin I (TnI) are the
markers recommended for diagnosis of acute myocardial
infarction [9]. With the implementation of assays with
improved analytical sensitivity (hs-Tn), the reliable determi-
nation of troponin, even at concentrations below the previ-
ously defined 99th percentile values, has become possible.
The limit of detection for the newest generation of hs-Tn assay
is 10- to 100-fold lower than that of traditional assays [10].
Although an increase in troponin concentration classically
indicates myocyte necrosis, several cellular processes other
than necrosis can induce troponin release. Among them is
increased cell wall permeability which may occur because
of ischemia [11]. Test-induced ischemia has been associated
with a quantifiable increase of troponin detectable with an
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ultrasensitive assay in proportion to the grade of ischemia,
that is, mild or moderate to severe [12]. In addition to provid-
ing diagnostic information, the troponin levels offer powerful
prognostic information even if detected in asymptomatic
adults and moreover several cardiovascular risk factors have
been shown to correlate with hs-Tn levels [13]. The emerging
awareness of ED as an early warning for vascular health and
possibly of silent CAD represents a unique opportunity to
improve preventive cardiovascular health in all adult men
who have persistent difficulty in achieving or maintaining an
erection [14]. However, it is vital for effective management
of the condition to isolate from this group of men those
at high risk of CAD in particular to avoid treating those
individuals who are not at risk of CAD and therefore who
do not need it. The aim of our investigation was the early
detection of cardiac injuries, even where no symptoms were
present, using hs-Tn assays, in patients who have had ED
symptoms for a fewmonths, more than three months but less
than one year, without known CAD risk factors. In fact, these
patients are particularly susceptible to the development of
CAD and would benefit the most from lifestyle modification
or appropriate medical management earlier.
2. Material and Methods
Out of a series of 590 filed ED cases studied in the period
of October 2009 to June 2011, we included in this study all
patients with a history of ED of more than 3 months but
less than one year. Exclusion criteria were clinical evidence
from the patient’s clinical history of coronary artery disease,
dyslipidemia, arterial hypertension, malignancies, renal fail-
ure, congestive heart failure, systemic inflammatory disease,
rheumatic disease, infection diseases, anemia, chronic liver
diseases, arrhythmias, trauma, and no current smoking and
vitamins supplementation or chronic drug assumption [15–
19]. This investigation conforms to the principles outlined in
the Declaration of Helsinki. Signed informed written consent
was obtained from all subjects before their participation
in the study. No ethical committee approval was required
because no additional blood was needed for this study, and
this was explained thoroughly to all patients, and also because
this procedure has been reported to be acceptable [20–23].
On the basis of the given inclusion and exclusion criteria
reported above, we selected a total of 120 ED patients who
were included in the study. Their clinical characteristics are
summarized in Table 1. The ED was classified as arteriogenic
origin in 40 patients and as nonarteriogenic origin in 48
patients and, finally, in 32 patients the ED was classified as
borderline. In our center, patients complaining of ED are
currently investigated by careful history-taking and clinical
andrological examination, then, a few days later, by a panel of
examinations, including blood tests such as hemoglobin, gly-
cated hemoglobin, glycemia, creatinine, high-sensitivity C-
reactive protein (hs-CRP), total andHDL cholesterol, triglyc-
erides, transaminases, testosterone, prolactin, 17-𝛽-estradiol,
urinalysis and 24 h urinary albumin excretion (microalbu-
minuria), the International Index of Erectile Function ques-
tionnaire (IIEF), and echo-color-Doppler of both cavernous
arteries.
Table 1: Clinical and laboratory features of patients with erectile
dysfunction. Values are reported as mean and standard deviation.
NA-ED
(𝑛 = 40)
A-ED
(𝑛 = 48)
BL-ED
(𝑛 = 32)
Patients data
Age (years) 52.0 ± 8.5 58.1 ± 7.3 50.0 ± 10.5
IIEF-5 score 12.8 ± 2.4 10.5 ± 2.6 11.6 ± 1.8
Laboratory
evaluation
Study
parameters
hs-cTnT
(pg/mL) 2.89 ± 5.01 4.32 ± 7.29 3.10 ± 4.18
hs-cTnI
(pg/mL) 4.72 ± 10.93 2.4 ± 6.25 0.79 ± 3.88
hs-CRP
(mg/L) 1.70 ± 1.78 3.09 ± 3.19
∗ 2.03 ± 2.79
Other
parameters
Creatinine
(mg/dL) 0.92 ± 0.16 0.95 ± 0.16 0.96 ± 0.15
Glucose
(mg/dL) 102.9 ± 6.3 93.0 ± 14.1 95.6 ± 10.8
ALT (U/L) 26.22 ± 15.76 23.10 ± 10.29 24.46 ± 8.29
AST (U/L) 23.56 ± 10.16 21.60 ± 5.71 27.29 ± 10.28
Total
cholesterol
(mg/dL)
200.36 ± 10.21 207.80 ± 11.72 205.21 ± 9.49
HDL
cholesterol
(mg/dL)
55.14 ± 13.90 50.30 ± 10.19 52.46 ± 15.82
LDL
Cholesterol
(mg/dL)
122.56 ± 11.53 133.60 ± 10.68 128.04 ± 10.40
Triglycerides
(mg/dL) 112.97 ± 62.23 123.90 ± 58.60 125.54 ± 59.02
HbA1c (%) 5.27 ± 0.50 5.77 ± 0.52 5.56 ± 0.44
17-ß-Estradiol
(pg/mL) 27.23 ± 8.29 29.17 ± 8.61 27.45 ± 10.57
Prolactin
(ng/mL) 8.59 ± 4.66 8.64 ± 3.43 9.23 ± 3.52
Testosterone
(ng/mL) 4.97 ± 2.50 4.13 ± 1.64 4.59 ± 1.29
NA-ED: nonarteriogenic erectile dysfunction; A-ED: arteriogenic erectile
dysfunction; BL-ED: borderline arteriogenic erectile dysfunction.
∗
𝑃 < 0.048 versus NA-ED.
The IIEF questionnaire [24] is a validated, self-
administered tool, but we only evaluated the answers to
the first five (erectile response dominium) of the fifteen
questions (IIEF-15, 1–5) [24, 25]. Possible scores for the
IIEF-5 range from 5 to 25; scores of 22–25 indicate normal
erectile function while scores of 21 or below indicate ED [25].
Penile echo-color-Doppler was done in basal conditions
and after intracavernous injection of 10 𝜇g prostaglandin
E1 (PgE1), and the peak systolic velocity (PSV) and end-
diastolic velocity (EDV) were recorded 5, 10, 15, 20, and
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25min after the injection in the proximal portion of the
penis. Patients were classified as “nonarteriogenic” (NA-
ED) when their PSV was ≥35 cm/sec or ≤35 cm/sec but
>25 cm/sec with concomitant EDV ≤0 cm/sec, “arteriogenic”
(A-ED) when their PSV was ≤20 cm/sec, and “borderline”
(BL-ED) with PSV between 25 and 21 cm/sec or with PSV
between 35 and 25 with concomitant EDV >0 cm/sec
[20–23, 26]. The erection quality was estimated 20min
after each injection. If a patient appeared stressed, he was
given a second injection of the same dose of PgE1 and
all measurements were repeated. Immediately before the
penile echo-color-Doppler, participants were placed in a
supine position and blood samples were drawn from a
cubital vein. Samples were centrifuged at 3000 rpm, for
10min. The serum was separated and stored at −80∘C until
analysis. All hs-TnT and hs-TnI were measured at the same
time.
Serum concentrations of hs-TnT (Troponin T immunoas-
say; RocheDiagnostics, Switzerland) and of hs-TnI (Troponin
I immunoassay; Johnson & Johnson, Italy) were measured
according to the manufacturer’s recommendations. The 99th
percentile value for our normal reference population was
18.3 pg/mL for hs-TnT and 37 pg/mL for hs-TnI measured
with a CV <10%.
All patients were referred to a cardiologist for evaluation
of ischemic heart disease (IHD). The evaluation consisted
of a comprehensive clinical history, physical examination,
and an electrocardiogram while resting and during treadmill
exercise.The diagnosis of ischemic heart disease relied on the
detection of a 1mm or more horizontal or downsloping ST-
segment depression, frequent ventricular premature beats,
or typical chest pain during the treadmill exercise test. In
addition, the Duke Treadmill Score (DTS) as developed by
Mark et al. [27] was calculated. The categories of risk based
on the DTS are low risk (DTS > +5), moderate risk (DTS −10
to +4), and high risk (DTS < −11) [28].
All the results are expressed as the mean ± standard
deviation. The data were not normally distributed and were
normalized by using the log or log-log transformation.
Undetectable values of hs-TnT and hs-TnI concentrations
were considered equal to 0 for statistical purpose. In this
regard, undetectable concentrations of hs-TnT were present
in 49 out of 120 patients studied (40.8%) and undetectable
concentrations of hs-TnI in 78 of the 120 studied patients
(65.0%). The statistical analysis was carried out by using
the ANOVA test taking into account the three groups of
patients. The association between IIEF-5 and laboratory
parameters was examined by Pearson’s correlation coefficient.
The estimate beta-power was equal to 0.004. 𝑃 value < 0.05
was considered significant.
3. Results
Of the 120men included in the study, 40 patients (33.3%)were
classified as having A-ED, 48 patients (40%) as having NA-
ED, and, finally, 32 patients (26.6%) as having BL-ED. In A-
ED (mean age 52 ± 8.5 years), NA-ED (mean age 58.1 ± 7.3
years), and BL-ED (mean age 50.0 ± 10.5 years) the mean
of IIEF values was 12.8 ± 2.4, 10.5 ± 2.6, and 11.6 ± 1.8,
respectively. There were no significant differences between
the three groups (𝑃 > 0.05). All the men had DTS > +5
without significant difference between the three groups (𝑃 >
0.05).
All our data of hs-TnT and hs-TnI concentrations were
in the reference range, as reported in Table 1. No significant
difference (𝑃 > 0.05) of serum concentration of both hs-TnT
and hs-TnI was found among the three groups of ED patients.
The hs-CRP values were higher in A-EDmen compared with
NA-ED (𝑃 = 0.048) but not compared with BL-ED (𝑃 =
0.136), while no significant difference was found between BL-
ED and NA-ED (𝑃 = 0.964). Spearman’s correlation analysis
demonstrated a negative correlation between serum hs-CRP
and IIEF-5 that reached the significance in A-ED (r = −0.480;
𝑃 = 0.031) but without reaching the significance in NA-ED
and BL-ED [29, 30]. No statistically significant differences
were found regarding the other laboratory parameters eval-
uated (i.e., creatinine, glucose, ALT, AST, total cholesterol,
HDL cholesterol, LDL cholesterol, triglycerides, HbA1c, 17-
𝛽-estradiol, prolactin, and testosterone) (Table 1).
4. Discussion
A consensus exists to consider ED an independent predictor
of CVD [31–36], including CAD [37], peripheral artery
disease [38], and stroke [39]. The early symptom of erectile
difficulty often occurs before the development of structural,
occlusive arterial disease andmay therefore be one of the first
signs of systemic vascular disease [14]. In other words, ED
could be a sentinel marker for the presence of silent vascular
disease in asymptomatic subjects. For this reason every effort
should be made to check if cardiovascular risks are present in
patients with ED or recognize when they begin to be present.
Clinical studies revealed that the onset of ED symptoms
occurs 2 to 3 years before CAD symptoms [40, 41] and 3 to
5 years before cardiovascular events [42, 43]. This relatively
long time lag offers important potential in estimating and,
ultimately, reducing cardiovascular risk in men with ED.
However, it should be stressed that the penis is not always the
most susceptible organ to inflammatory and atherosclerotic
changes. Accordingly, although ED frequently precedes the
onset of CAD, a considerable proportion of patients have
CAD without concomitant ED, and vice versa, proving that
the clinical course of atherosclerosis is multifaceted and not
fully predictable. In diseases like ED, there is a need for
a marker with a high negative predictive value for cardiac
injury (ability to “rule out” the disease in patients with ED
based on high sensitivity). In other words, it is imperative
that a biomarker should ensure that ED cases at high risk
of future cardiac events are not missed, because of the great
benefit of treating these patients with a proven safe treatment.
Cardiac troponins I and T are considered the most sensitive
and specific biochemical markers of myocardial damage and
the increased analytical sensitivity of the new generation
methods demonstrated that measurable troponin was also
present in the blood of almost 100% of healthy adults [44–
46].
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The aim of the study was to assess the presence of
cardiovascular involvement with the measurement of both
hs-TnT and hs-TnI levels in ED patients in order to begin the
appropriate treatment quickly following the first symptoms to
prevent significant cardiovascular events.
The populations studiedwere homogeneouswithout clin-
ical evidence of atherosclerotic diseases; all men had normal
ECG without ST-segment depression in exercise stress test
and the DTS > +5.
Our results, using the measurement of hs-TnT or hs-TnI,
at least in our experimental conditions, exclude the presence
of cardiovascular injury in all patients with ED for less than
one year and also in those of arteriogenic etiology. The
fact that no differences were found among the three groups
excludes the possibility of other statistical analyses such as the
exploration of an optimal cut-point to differentiate the three
groups.
In our patients we found that the serum concentrations of
hs-CRP are higher in A-ED and the levels are associated with
penile arterial disease severity assessed with IIEF-5. These
data agree with those previously reported [29, 46–48]. In
particular, plasma levels of hsCRP were found significantly
higher in patients with ED and furthermore associated with
penile arterial disease severity in men with ED without
clinically apparent cardiovascular disease [30].
The number of patients included in this study seems to
be low, but it must be considered that the population studied
was carefully selected. In addition, the patients studied hadno
clinical evidence of atherosclerotic diseases and were free of
the common risk factors associated with generalized penile
arterial insufficiency such as hypertension, hyperlipidemia,
cigarette smoking, diabetes mellitus, and pelvic irradiation.
This is the first study to compare the value of troponin as a
marker of cardiovascular disease before clinical symptoms in
ED patients. Finally, we do not know whether troponin (T or
I) may add information by adding the determination of other
biomarkers such as NT-proBNP, as recently suggested [49,
50], or clinical variables such as echocardiography. Given the
complementary and independent prognostic value of various
markers, a “multimarker” approach in men with ED may be
an effective strategy to improve prediction of cardiovascular
risk beyond the use of traditional risk factors in daily clinical
practice.
In conclusion, this study shows that the measurement of
hs-TnT or hs-TnI levels allows us to exclude the presence
of cardiovascular disease in patients with ED. The reason is
probably the short history of ED, which was of less than one
year. Longitudinal study is currently in progress to follow
the level of hs-Tn (I and T) in this selected group of men,
particularly in A-ED, in order to recognize when the heart
begins to be affected by the process of atherosclerosis, before
clinical symptoms. At present, we know the basal levels
of both hs-Tn types in all our patients, and knowing the
reference change values (RCV) [51–54], we can recognize
when the level will increase over the RCV, even if it remains
within the reference interval. Knowing that a minimum
clinical change if present would indeed be diagnostically
useful.
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